Huadao Biopharma has collected a $14.5m series B investment from NKY Medical Holdings to build out its cancer treatment technology.
China-based oncology technology developer Huadao Biopharma has completed a RMB100m ($14.5m) series B round led by chemical developer NKY Medical Holdings.
The round also included a commitment from Ren Dalong, vice-president at pharmaceutical intermediate provider NKY Medical, according to a statement on Huadao’s WeChat account.
Founded in 2017, Huadao is developing chimeric antigen receptor (CAR) T-cell therapies, which are intended to alter the patient’s cells to help treat forms of cancer. It will use the series B capital to support…
